Positive Phase III mRNA Vaccine Combo Trial Boosts Moderna by $44 Billion; A-share Pharma Down 2.38% in Week
A Phase III trial of an mRNA tumor vaccine combination therapy yielded positive top-line results, lifting the developer's market value by more than $44 billion in a single day. In the A-share market, the pharmaceutical and biotech sector fell 2.38% for the week ended August 22, ranking 23rd among 31 Shenwan primary industries. The Shanghai Composite and CSI 300 dropped 0.56% and 1.01%, respectively. Sub-sectors showed mixed performance, with biological products and medical devices down 0.36% and 0.58%, while chemical pharmaceuticals and medical commerce fell over 4.2%.
A Phase III clinical trial of an mRNA tumor vaccine combination therapy achieved positive top-line results, leading to a significant rise in the developer's market value. Data showed the company's market capitalization increased by more than $44 billion in a single day. Following the news, several related themes in the A-share market fluctuated, with the pharmaceutical sector initially staging a broad rally before pulling back.
During the week of August 17-22, the A-share pharmaceutical and biotech sector fell 2.38% cumulatively, ranking 23rd among the 31 Shenwan primary industry sectors for weekly performance. Over the same period, the Shanghai Composite Index fell 0.56% and the CSI 300 Index fell 1.01%.
Among pharmaceutical sub-sectors, biological products and medical devices posted smaller declines, down 0.36% and 0.58% respectively for the week. Medical services fell 1.32%, while traditional Chinese medicine dropped nearly 3.5%. Medical commerce and chemical pharmaceuticals were weaker, each falling more than 4.2%.